TY - JOUR
T1 - Emerging CAR T Cell Strategies for the Treatment of AML
AU - Vishwasrao, Paresh
AU - Li, Gongbo
AU - Boucher, Justin C.
AU - Smith, D. Lynne
AU - Hui, Susanta K.
N1 - Funding Information:
Funding: Research reported in this publication is partly supported by National Institutes of Health grant (2R01CA154491-01) Acknowledgments: Aashish Pande is acknowledged for his input in designing the figures, and Trupti Palav, Krystal Valdenegro, Nicolette Pollock and Shiny Nair are acknowledged for editing the manuscript.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Engineered T cells expressing chimeric antigen receptors (CARs) on their cell surface can redirect antigen specificity. This ability makes CARs one of the most promising cancer therapeutic agents. CAR-T cells for treating patients with B cell hematological malignancies have shown impressive results. Clinical manifestation has yielded several trials, so far five CAR-T cell therapies have received US Food and Drug Administration (FDA) approval. However, emerging clinical data and recent findings have identified some immune-related toxicities due to CAR-T cell therapy. Given the outcome and utilization of the same proof of concept, further investigation in other hematological malignancies, such as leukemias, is warranted. This review discusses the previous findings from the pre-clinical and human experience with CAR-T cell therapy. Additionally, we de-scribe recent developments of novel targets for adoptive immunotherapy. Here we present some of the early findings from the pre-clinical studies of CAR-T cell modification through advances in genetic engineering, gene editing, cellular programming, and formats of synthetic biology, along with the ongoing efforts to restore the function of exhausted CAR-T cells through epigenetic remodeling. We aim to shed light on the new targets focusing on acute myeloid leukemia (AML).
AB - Engineered T cells expressing chimeric antigen receptors (CARs) on their cell surface can redirect antigen specificity. This ability makes CARs one of the most promising cancer therapeutic agents. CAR-T cells for treating patients with B cell hematological malignancies have shown impressive results. Clinical manifestation has yielded several trials, so far five CAR-T cell therapies have received US Food and Drug Administration (FDA) approval. However, emerging clinical data and recent findings have identified some immune-related toxicities due to CAR-T cell therapy. Given the outcome and utilization of the same proof of concept, further investigation in other hematological malignancies, such as leukemias, is warranted. This review discusses the previous findings from the pre-clinical and human experience with CAR-T cell therapy. Additionally, we de-scribe recent developments of novel targets for adoptive immunotherapy. Here we present some of the early findings from the pre-clinical studies of CAR-T cell modification through advances in genetic engineering, gene editing, cellular programming, and formats of synthetic biology, along with the ongoing efforts to restore the function of exhausted CAR-T cells through epigenetic remodeling. We aim to shed light on the new targets focusing on acute myeloid leukemia (AML).
KW - Acute myeloid leukemia (AML)
KW - Chimeric antigen receptor (CAR)-T cells
KW - Co-stimulatory domains
KW - Preclinical model
KW - Single-chain variable fragment (scFv)
UR - http://www.scopus.com/inward/record.url?scp=85125195951&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125195951&partnerID=8YFLogxK
U2 - 10.3390/cancers14051241
DO - 10.3390/cancers14051241
M3 - Review article
C2 - 35267549
AN - SCOPUS:85125195951
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 5
M1 - 1241
ER -
